TII
19.4.2021 13:37:10 CEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Cryptography Research Centre (CRC) has launched the UAE’s first secure cloud technologies programme which will boost advanced technologies that enhance data privacy and cloud encryption schemes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005461/en/
TII said that its secure cloud technologies programme aims to advance Privacy Enhancing Technologies (PETs), including fully homomorphic encryption (FHE), a form of encryption that permits users to perform computations on encrypted data without first decrypting it, and secure multi-party computation (MPC), creating methods for parties to jointly compute a function over their inputs while keeping those inputs private. This line of research will be coupled with the field of verifiable computation for Machine Learning, to cater for a proof of correctness for an Inference-as-a-Service use case when data privacy is not required.
The research team in-charge is also joining efforts with the hardware cryptography team to develop FHE hardware accelerators to offload certain computing tasks onto specialised hardware components within the system, enabling greater efficiency.
Speaking on the announcement, His Excellency Faisal Al Bannai, Secretary General of the Advanced Technology Research Council (ATRC), said: “Cloud computing has undergone significant growth in the last decade which has raised security and privacy challenges. Traditional approaches still require data to be decrypted for processing and a cloud-centralised key management system, thus exposing both the data and the secret key to cloud providers. This underscores the importance of launching this programme by our researchers at TII’s Cryptography Research Centre.”
Dr Najwa Aaraj, Chief Researcher at the Cryptography Research Centre , said: “FHE allows performing arbitrarily complex, dynamically chosen computations on data while it remains encrypted despite not having the secret decryption key. Moreover, FHE is a key enabler for multi-party computation (MPC) protocols implementing oblivious federated learning models, which are on the rise in critical infrastructure data transfer.”
“TII’s implementation of secret sharing-based MPC leverages FHE building blocks for providing active security and optimised preprocessing to speed up the oblivious implementation of Machine Learning models,” she said. Moreover “FHE remains computationally intensive. Researchers at TII are also developing hardware accelerators driven by principal components and operations analysis and targeted enhancements using ASICs and multiple FPGA platforms. Further direction includes implementation on embedded processors with an extensible instruction set architecture.”
Cryptography Research Centre, one of seven initial dedicated research centres at Technology Innovation Institute, employs and collaborates with scientists in multiple cryptography fields such as post-quantum cryptography, hardware-based cryptography, lightweight cryptography, cryptanalysis, cryptographic protocols, and cloud encryption schemes, amongst others. The Centre is also among the few internationally that brings together theoretical and applied cryptographers in a research-oriented setting. The cryptographers collaborate on breakthrough research projects that lead to innovative outcomes.
For more information about Technology Innovation Institute (TII) visit www.tii.ae
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005461/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
